At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 41 enrolled
Drug / intervention
PXD101 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Clinical Trial of PXD101 in Combination With Idarubicin in Patients With AML Not Suitable for Standard Intensive Therapy
In Brief
A Phase 2 clinical trial evaluating PXD101 and idarubicin for Acute Myeloid Leukemia. Completed, enrolled 41 participants across 6 sites in 3 countries.
Detailed Summary
An open-label, non-randomized, multi-centre, Phase I/II trial to assess the efficacy and safety of 2 schedules of PXD101 in combination with idarubicin in patients with AML not suitable for standard intensive therapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Myeloid Leukemia
CountriesFrance, Germany, United Kingdom
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartAug 2007
First PostedApr 2009
Primary CompletionMay 2009
Study CompletionApr 2012
TodayJul 2026
First PostedApr 9, 2009
Enrollment StartAug 1, 2007
Primary CompletionMay 1, 2009
Study CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 17.2 years ago
Interventions
PXD101drug
idarubicindrug